Skip to main content
padlock icon - secure page this page is secure

Why CCR5 is Chosen as the Target for Stem Cell Gene Therapy for HIV Infection?

Buy Article:

$106.34 + tax (Refund Policy)

Since the first case reported in 1981, more than 60 million individuals have succumbed to HIV worldwide. Although great efforts have been put forth in developing therapeutic drugs and effective vaccines for the treatment and prevention of HIV infection, these efforts are not correlated to the reported case of cured HIV infection. The first case of cured HIV infection, from allogenic stem cell transplantation, may shed light on future prevention and therapy of HIV infection. The choice of gene target, however, must first be evaluated regarding stem cell based gene therapy for HIV infection. Out of the tens of genes that had shown anti-HIV infection potentials, CCR5 was described to be effective in stem cell based gene therapy in 2005. Here, we appreciate the clinical observations that directly led to the choice of CCR5, rather than other genes for stem cell gene therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: March 1, 2012

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more